Research programme: antibacterials - Actelion

Drug Profile

Research programme: antibacterials - Actelion

Alternative Names: AB-1; AB-2; AB-3; Actelion-10; Actelion-11; Actelion-9; Injectable antibacterials - Actelion; Oral antibacterials - Actelion

Latest Information Update: 27 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Actelion Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Bacterial infections; Nosocomial infections

Most Recent Events

  • 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Switzerland (Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top